Late-breaking results from first-in-human clinical experience of NUVISION™ Ultrasound Catheter to be presented
Additional presentations include data highlighting the role of mapping software, diagnostic catheters, therapeutic catheters, and digital technologies in advancing cardiac arrhythmia treatment
Biosense Webster on-site booth will host a variety of interactive experiences including product trials, hands-on demonstrations, and education
IRVINE, Calif. – July 27, 2021 – Biosense Webster, the global leader in cardiac arrhythmia treatment and part of Johnson & Johnson Medical Devices Companies*, announced today that data from 16 company-sponsored studies will be presented at Heart Rhythm 2021, the Heart Rhythm Society's annual meeting, taking place in Boston from July 28-31. The data presented reflects Biosense Webster’s continued innovation and commitment to advancing science in the field of electrophysiology with the goal of improving patient outcomes. Presentation topics include new data on novel technologies spanning CARTO™ mapping technology, diagnostic catheters, therapeutic catheters, and the role of digital technologies in advancing cardiac arrhythmia treatment. Additionally, two abstracts will be presented highlighting real-world data on atrial fibrillation treatment outcomes.
“We look forward to greeting many of our colleagues live and in-person in Boston at Heart Rhythm 2021, an event that highlights science, showcases innovation and fosters strong connections within electrophysiology,” said Uri Yaron, Worldwide President, Biosense Webster, Inc. “We are particularly excited to highlight data from studies supported by Biosense Webster and our innovations, and welcome physicians to experience our latest technology as we work together to advance the future of AFib treatment for patients around the world.”
Interactive In-Booth Experiences
As part of the Biosense Webster booth, a variety of interactive experiences will be available including hands-on demonstrations of the new OCTARAY™ Mapping Catheter with TRUEref™ Technology, CARTONET cloud-based software solution, and NUVISION™ Ultrasound Catheter with imaging support from GE Healthcare Vivid™ Ultra Edition ultrasound systems.
Key Scientific Presentations
Data from 16 Biosense Webster-sponsored studies will be presented at Heart Rhythm 2021, spanning key topics in electrophysiology – including late-breaking science on 4D ICE technology, as well as presentations outlining post-approval data using optimized index tag-guided catheter ablation, preclinical safety data using irreversible pulsed field ablation, and several presentations focusing on the use of cloud sharing and artificial intelligence.
- Mapping and ablation of conduction channels in the ischemic ventricular scar using Ripple Mapping. Poster session II / B-PO02. Presented July 29 from 9:30am-12:00pm EST by Dr. Prapa Kanagaratnam.
- RIPPLE-VT Study: Multicentre, prospective evaluation of conduction channel entrance ablation in ischemic ventricular tachycardia with latest scar potential elimination without direct ablation as an endpoint. Poster session V / B-PO05. Presented July 30 from 1:20-4:00pm EST by Dr. Prapa Kanagaratnam and Dr. Demosthenes Katritsis.
- Atrial Fibrillation termination and freedom from Atrial Fibrillation is associated with ablation of atrial regions with higher ripple frequency. Poster session III / B-P003-088. Presented July 29 from 3:40-3:50pm EST by Dr. Daniel Melby.
- Automated Identification of VT Ablation Targets: Multicenter Validation and Workflow Characterization. Poster session V / B-PO05. Presented July 30 from 1:30-4:00pm EST by Dr. Kumaraswamy Nanthakumar.
Therapeutic Catheters and Technology
- Subchronic Versus Chronic Safety Assessment Of A Circular Irreversible Electroporation Catheter Design And A Pulse Field Ablation Generator. Poster session IV / B-PO04. Presented July 30 from 9:30 am-12:00 pm EST by Dr. Massimo Grimaldi.
- Reproducibility of Optimized Tag Index-Guided Catheter Ablation for Pulmonary Vein Isolation in Patients with Paroxysmal Atrial Fibrillation – The SURPOINT Post-Approval Study. Oral Presentation B-AB21. Presented July 30 from 1:45 pm-1:55 pm EST by Dr. Luigi Di Biase.
Diagnostic and Imaging Catheters
- Late-Breaking Science: First-in-Human Clinical Experience with a Novel 4D ICE Catheter during Catheter Ablation and LAA Closure Procedures. Late Breaking Science B-LBCT04. Presented July 30 from 1:45 pm-2:45 pm EST by Dr. Vivek Reddy.
- Simultaneous Ultra-High Resolution Optical Mapping And Catheter Mapping In A Langendorff-Perfused Swine Heart Model To Identify Atrial Fibrillation Rotors By Catheter Mapping. Poster session V / B-PO05. Presented July 30 from 1:30-4:00pm EST by Dr. Hiroshi Nakagawa.
- Leveraging A Cloud Based Artificial Intelligence Engine to Analyze Data from REAL AF Registry. Poster session II / B-PO02. Presented July 29 from 9:30 am-12:00 pm EST by Dr. Joshua Silverstein.
- Cloud-based Lesion Analysis with CARTONET Identifies Catheter Stability as a Key Factor Promoting Acute First Pass Pulmonary Vein Segment Isolation. Poster session III / B-PO03. Presented July 29 from 2:00 pm-4:30 pm EST by Dr. John Whitaker.
- Anatomic Lesion Location During Pulmonary Vein Isolation Impacts Ablation Parameters and Independently Predicts Impedance Change and Regional First Pass Isolation: An Analysis of 8395 Lesions. Poster session III / B-PO03. Presented July 29 from 2:00 pm-4:30 pm EST by Dr. Omar Kreidieh.
- Ablation Delivery Parameters Predict Impedance Decrease During Atrial Fibrillation Ablation Via A Cloud Artificial Intelligence System Analysis. Poster session III / B-PO03. Presented July 29 from 2:00 pm-4:30 pm EST by Dr. Clint Thurber.
- Incidence And Characteristics Of Carinal Ablation In Pulmonary Vein Isolation. Poster session IV / B- PO04. Presented July 30 from 9:30 am-12:00 pm EST by Dr. Toshimasa Okabe.
Real-World AFib Outcomes
- Earlier Versus Later Treatment With Ablation Among Young Patients With Newly Diagnosed Atrial Fibrillation. Poster session IV / B-PO04. Presented July 30 from 9:30 am-12:00 pm EST by Dr. Robert D’Angelo.
- Evaluating Outcomes of Same-day Discharge After Catheter Ablation for Atrial Fibrillation in a Real-World Cohort. Poster session IV / B-PO04. Presented July 30 from 9:30 am-12:00 pm EST by Dr. Michael Field.
- High Frequency Low Tidal Volume Ventilation In Atrial Fibrillation Ablation Safely Reduces Radiofrequency And Procedure Time. Poster session II / B-PO04. Presented July 30 from 9:30 am-12:00 pm EST by Dr. Jose Osorio.
For more information about Biosense Webster’s presence at Heart Rhythm 2021, visit BiosenseWebsterHRS.com.
About Biosense Webster
Biosense Webster is the global market leader in the science and technology behind the diagnosis and treatment of cardiac arrhythmias. Part of the Johnson & Johnson Family of Companies, the specialized medical-technology company is headquartered in Irvine, Calif., and works across the world to advance the tools and solutions that help electrophysiologists identify, treat, and deliver care. Learn more at biosensewebster.com and connect on LinkedIn and Twitter.
About Johnson & Johnson Medical Devices Companies
At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopaedics, vision and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding VARIPULSE™ Catheter and NUVISION™ Ultrasound Catheter. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Biosense Webster, Inc., any of the other Johnson & Johnson Medical Devices Companies and/or Johnson & Johnson. Risks and uncertainties include but are not limited to uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Biosense Webster, Inc., the Johnson & Johnson Medical Devices Companies, nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
* The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment.
© Biosense Webster, Inc. 2021 [182434-210707]